BioCorRx acquires additional 12.15% of subsidiary via stock-for-stock exchange with insiders

BioCorRx Inc.

Entered stock exchange agreement with CEO, President, and board member to transfer 1,215 subsidiary shares for 2,263,371 parent shares.
Exchange closed March 27, 2026; intended as tax-free reorganization under Section 368(a)(1)(B).
Subsidiary BioCorRx Pharmaceuticals was ~12.15% minority stake acquired; no cash consideration paid.
Parent shares are unregistered, issued under Section 4(a)(2) exemption; registration rights granted to shareholders.
Part of Plan of Reorganization to obtain control of subsidiary under Section 368(c) of the Code.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioCorRx Inc. entered into Agreement with Lourdes Felix, Louis C Lucido, and Kent Emry (effective 2026-03-26).

Action: entry
Agreement: equity purchase
Counterparty: Lourdes Felix, Louis C Lucido, and Kent Emry
Effective: 2026-03-26

Exact text from the filing

On March 26, 2026, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a stock exchange agreement (the “Agreement”) with Lourdes Felix, Chief Executive Officer of the Company and a member of the Company’s Board of Directors (the “Board”), Louis C Lucido, President of the Company and a member of the Board, and Kent Emry (collectively with Lourdes Felix and Louis C Lucido, the “Shareholders”), a member of the Board, pursuant to which the Shareholders agreed to transfer to the Company an aggregate of 1,215 shares of common stock of BioCorRx Pharmaceuticals, Inc., a Nevada corporation, which is a majority-owned subsidiary of the Company (the “Subsidiary”), representing in the aggregate approximately 12.15% of the outstanding common stock of the Subsidiary, in exchange for an aggregate of 2,263,371 shares (the “Parent Shares”) of the Company’s common stock

View on SEC.gov

Browse all material agreements →

BioCorRx Inc. filing history →

Source: SEC EDGAR

accession 0001477932-26-001957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.